See more : Luks Group (Vietnam Holdings) Company Limited (LKSGF) Income Statement Analysis – Financial Results
Complete financial analysis of C4X Discovery Holdings plc (C4XD.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of C4X Discovery Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Maeda Kosen Co., Ltd. (7821.T) Income Statement Analysis – Financial Results
- Widgie Nickel Limited (WIN.AX) Income Statement Analysis – Financial Results
- Daehyun Co.,Ltd. (016090.KS) Income Statement Analysis – Financial Results
- Artivion, Inc. (CRY) Income Statement Analysis – Financial Results
- AnaptysBio, Inc. (ANAB) Income Statement Analysis – Financial Results
C4X Discovery Holdings plc (C4XD.L)
About C4X Discovery Holdings plc
C4X Discovery Holdings plc operates as a drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality. The company's product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation and autoimmune diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer. It has partnerships with Sanofi, GEN-COVID, LifeArc, Indivior PLC, Phoremost, AstraZeneca UK Limited, and Evotec SE. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was incorporated in 2007 and is based in Manchester, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.71M | 2.70M | 5.64M | 0.00 | 0.00 | 7.06M | 143.00K | 279.00K | 312.00K | 619.00K | 736.00K | 440.00K |
| Cost of Revenue | 38.00K | 130.00K | 90.00K | 485.00K | 191.00K | 188.00K | 3.00K | 12.00K | 112.00K | 23.00K | 1.00K | 1.00K |
| Gross Profit | 1.67M | 2.57M | 5.55M | -485.00K | -191.00K | 6.88M | 140.00K | 267.00K | 200.00K | 596.00K | 735.00K | 439.00K |
| Gross Profit Ratio | 97.78% | 95.18% | 98.40% | 0.00% | 0.00% | 97.34% | 97.90% | 95.70% | 64.10% | 96.28% | 99.86% | 99.77% |
| Research & Development | 10.89M | 6.69M | 5.31M | 4.52M | 10.59M | 6.99M | 6.10M | 3.70M | 2.22M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.19M | 3.67M | 3.18M | 2.71M | 3.05M | 2.61M | 2.53M | 1.82M | 904.00K | 1.82M | 1.32M | 869.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.19M | 3.67M | 3.18M | 2.71M | 3.05M | 2.61M | 2.53M | 1.82M | 904.00K | 1.82M | 1.32M | 869.00K |
| Other Expenses | 0.00 | 2.73M | 2.95M | 2.34M | 0.00 | 3.03M | 0.00 | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.09M | 13.09M | 11.45M | 9.57M | 13.64M | 9.60M | 8.63M | 7.06M | 4.06M | 1.82M | 1.32M | 869.00K |
| Cost & Expenses | 15.12M | 13.22M | 11.54M | 9.57M | 13.64M | 9.60M | 8.64M | 7.07M | 4.18M | 1.84M | 1.32M | 870.00K |
| Interest Income | 22.00K | 0.00 | 1.00K | 5.00K | 15.00K | 7.00K | 3.00K | 32.00K | 49.00K | 1.00K | 0.00 | 0.00 |
| Interest Expense | 24.00K | 12.00K | 15.00K | 18.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 119.00K | 89.00K | 0.00 |
| Depreciation & Amortization | 338.00K | 243.00K | 376.00K | 490.00K | 191.00K | 188.00K | 179.00K | 88.00K | 26.00K | 13.00K | 14.00K | 8.00K |
| EBITDA | -13.05M | -10.28M | -5.52M | -9.08M | -13.45M | -2.35M | -8.31M | -6.70M | -3.79M | -1.21M | -573.00K | -422.00K |
| EBITDA Ratio | -763.39% | -380.84% | -97.78% | 0.00% | 0.00% | -33.20% | -5,813.99% | -2,401.79% | -1,214.10% | -194.83% | -77.85% | -95.91% |
| Operating Income | -13.41M | -10.52M | -5.89M | -9.57M | -13.64M | -2.53M | -8.49M | -6.79M | -3.86M | 1.22M | 587.00K | 430.00K |
| Operating Income Ratio | -784.44% | -389.85% | -104.45% | 0.00% | 0.00% | -35.86% | -5,939.16% | -2,433.33% | -1,238.14% | 197.09% | 79.76% | 97.73% |
| Total Other Income/Expenses | -2.00K | -12.00K | -14.00K | -13.00K | 15.00K | 7.00K | 3.00K | 32.00K | 49.00K | -2.56M | -1.26M | -860.00K |
| Income Before Tax | -13.42M | -10.53M | -5.91M | -9.58M | -13.62M | -2.53M | -8.49M | -6.76M | -3.81M | -1.34M | -676.00K | -430.00K |
| Income Before Tax Ratio | -784.56% | -390.29% | -104.70% | 0.00% | 0.00% | -35.76% | -5,937.06% | -2,421.86% | -1,222.44% | -216.16% | -91.85% | -97.73% |
| Income Tax Expense | -2.31M | -2.37M | -2.06M | -1.79M | -2.71M | -1.39M | -1.71M | -1.44M | -750.00K | -220.00K | -195.00K | -109.00K |
| Net Income | -11.11M | -8.16M | -3.84M | -7.79M | -10.91M | -1.14M | -6.78M | -5.32M | -3.06M | -1.12M | -481.00K | -321.00K |
| Net Income Ratio | -649.77% | -302.33% | -68.13% | 0.00% | 0.00% | -16.07% | -4,742.66% | -1,907.17% | -982.05% | -180.61% | -65.35% | -72.95% |
| EPS | -0.04 | -0.04 | -0.02 | -0.08 | -0.19 | -0.02 | -0.17 | -0.17 | -0.11 | -0.04 | -0.02 | -0.01 |
| EPS Diluted | -0.04 | -0.04 | -0.02 | -0.08 | -0.19 | -0.02 | -0.17 | -0.17 | -0.11 | -0.04 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 251.10M | 228.68M | 196.26M | 96.12M | 58.67M | 47.13M | 40.67M | 32.01M | 28.81M | 31.37M | 31.37M | 31.37M |
| Weighted Avg Shares Out (Dil) | 251.10M | 228.68M | 196.26M | 96.12M | 58.67M | 48.49M | 40.67M | 32.01M | 28.81M | 31.37M | 31.37M | 31.37M |
Source: https://incomestatements.info
Category: Stock Reports